cancer
gene
therapi
face
problem
common
form
gene
therapi
name
lack
safe
effici
vector
deliv
gene
interest
diseas
site
anim
virus
shown
capabl
gene
deliveri
requir
elimin
nativ
tropism
mammalian
cell
altern
receptor
hajit
et
al
hajit
result
reduc
efficaci
allen
et
al
ghosh
barri
hajit
et
al
hajit
incorpor
target
peptid
deriv
vivo
phage
display
screen
viral
vector
attempt
littl
success
either
ligand
destroy
vector
vector
destroy
ligand
ghosh
barri
hajit
solut
limit
may
use
bacteriophag
gene
deliveri
vehicl
hajit
et
al
hajit
larocca
et
al
poul
mark
elimin
need
transfer
peptid
phage
display
eukaryot
viru
nativ
tropism
mammalian
cell
need
circumv
bacteriophag
safe
target
ligand
display
capsid
specif
mammalian
receptor
system
administr
hajit
unfortun
phage
particl
consid
poor
vector
nevertheless
evolv
infect
bacteria
therefor
intrins
strategi
deliv
gene
mammalian
cell
overcom
limit
recent
gener
improv
version
vector
hybrid
two
singl
strand
dna
virus
viru
aav
phage
term
aavphag
aavp
within
novel
vector
target
phage
capsid
serv
vehicl
deliv
recombin
raav
mammalian
dna
cassett
incorpor
intergenom
region
bacteriophag
genom
hajit
et
al
vector
show
superior
gene
deliveri
compar
regular
phage
vector
gene
express
vivo
system
deliveri
hajit
et
al
found
improv
mammalian
transduct
effici
associ
sever
factor
improv
fate
deliv
gene
mainten
entir
mammalian
transgen
cassett
better
persist
episom
dna
format
concatam
aav
transgen
cassett
hajit
et
al
previou
studi
use
aavp
display
cyclic
cdcrgdcfc
peptid
ligand
target
overexpress
integrin
tumor
therapeut
gene
success
deliv
tumor
site
mice
rat
spare
normal
organ
intraven
administr
hajit
et
al
tandl
et
al
trepel
et
al
recent
studi
carri
direct
nation
cancer
institut
usa
elegantli
confirm
potenti
technolog
paoloni
et
al
target
aavp
use
deliv
cytokin
tumor
necrosi
cancer
diagnos
pet
dog
repeat
dose
prove
safe
result
complet
erad
aggress
tumor
dog
paoloni
et
al
clear
aavp
repres
new
gener
vector
promis
howev
due
inher
limit
bacteriophag
need
improv
enabl
overcom
intracellular
barrier
mammalian
cell
phage
intern
assay
shown
cell
vitro
intern
target
phage
via
endocytosi
cell
actual
express
transgen
hajit
et
al
probabl
due
fact
unlik
eukaryot
virus
bacteriophag
strategi
evad
barrier
infect
agent
mammalian
cell
present
proteasom
one
barrier
enzym
respons
degrad
mani
cytosol
protein
eg
misfold
protein
cyclin
transcript
factor
process
foreign
protein
prior
deploy
cellular
immun
respons
groll
et
al
kisselev
tanaka
et
al
numer
previou
studi
report
proteasom
obstacl
eukaryot
viral
vector
monahan
et
al
furthermor
cancer
possess
elev
level
proteasom
activ
chen
dou
kisselev
wu
et
al
would
therefor
seem
like
activ
proteasom
repres
one
possibl
barrier
effici
deliveri
aavp
vector
cancer
cell
report
investig
efficaci
target
gene
deliveri
cancer
presenc
proteasom
inhibitor
calpain
inhibitor
llnl
llnl
peptid
aldehyd
inhibitor
revers
inhibit
proteasom
activ
kisselev
goldberg
lu
et
al
masdehor
et
al
vinitski
et
al
wide
use
proteasom
inhibit
studi
gartel
granot
et
al
lu
et
al
found
combin
proteasom
inhibitor
result
significantli
improv
report
gene
express
vitro
vivo
better
tumor
cell
kill
vector
alon
next
establish
improv
efficaci
associ
better
persist
aavp
particl
vitro
vivo
increas
polyubiquitin
aavp
coat
protein
use
combin
proteasom
inhibitor
result
strongli
suggest
supplementari
proteasom
inhibit
consid
potenti
aavp
vector
explor
human
embryon
kidney
cell
line
purchas
american
type
cultur
collect
atcc
human
melanoma
cell
gift
dr
david
cheresh
univers
california
la
jolla
human
glioblastoma
cell
cancer
research
uk
rat
glioblastoma
cell
provid
dr
hrvoje
milet
univers
bergen
norway
cell
line
maintain
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
fetal
bovin
serum
fb
sigma
penicillin
unitsml
sigma
streptomycin
sigma
mm
sigma
cell
cultur
humidifi
atmospher
passag
everi
day
reach
confluenc
assess
tumor
cell
kill
vitro
cell
incub
medium
contain
ganciclovir
gcv
gcv
renew
daili
cell
count
use
trypan
methodolog
mitochondri
activ
measur
cellular
viabil
measur
mtt
diphenyltetrazolium
bromid
assay
use
determin
viabil
cell
follow
treatment
sigma
calpain
inhibitor
llnl
sigma
cell
plate
densiti
cellswel
well
plate
nun
c
stock
solut
mm
mm
llnl
prepar
use
dimethyl
sulfoxid
dmso
sigma
cell
treat
vari
concentr
llnl
complet
medium
contain
llnl
drug
ad
cell
triplic
h
proteasom
inhibit
medium
remov
replac
fresh
medium
mtt
assay
carri
h
later
follow
manufactur
instruct
use
previous
report
aavp
vector
cytomegaloviru
cmv
promot
drive
mammalian
express
cassett
contain
report
therapeut
transgen
hajit
et
al
target
phage
viral
particl
amplifi
isol
purifi
cultur
supernat
host
bacteria
esherichia
coli
describ
hajit
et
al
phage
particl
filter
titrat
infect
host
bacteria
follow
coloni
count
agar
plate
express
transduc
unit
describ
hajit
et
al
cell
transduct
aavp
vector
perform
recent
describ
detail
protocol
hajit
et
al
briefli
cell
count
plate
plate
grown
h
reach
confluenc
next
vector
incub
cell
h
ml
total
volum
medium
ratio
tu
vector
per
cell
follow
medium
chang
medium
plu
serum
typic
vector
without
ligand
serv
neg
control
experi
indic
treatment
proteasom
inhibitor
llnl
initi
vector
transduct
continu
h
analysi
cell
transduct
efficaci
vitro
target
vector
carri
use
green
fluoresc
protein
gfp
well
firefli
luciferas
luc
report
transgen
gfp
express
cell
monitor
daili
use
nikon
eclips
fluoresc
microscop
fit
nikon
digit
camera
gfp
posit
cell
count
express
averag
five
field
view
luciferas
report
transgen
express
cell
determin
use
promega
luciferas
assay
kit
follow
manufactur
protocol
quantifi
use
promega
plate
reader
normal
protein
level
determin
bradford
assay
addit
data
normal
vector
cell
seed
incub
h
reach
confluenc
next
cell
transduc
target
carri
herp
simplex
viru
thymidin
kinas
hsvtk
gene
presenc
absenc
proteasom
inhibitor
describ
gcv
ad
cell
day
post
vector
transduct
renew
daili
viabl
cell
count
h
h
post
gcv
treatment
use
trypan
methodolog
melanoma
cell
seed
coverslip
plate
next
day
cell
approxim
confluenc
incub
phage
presenc
absenc
h
serum
free
medium
overnight
complet
medium
describ
next
cell
wash
phosphat
buffer
salin
pb
fix
pb
contain
paraformaldehyd
cell
incub
min
mm
ammonium
chlorid
quench
free
aldehyd
group
fixat
permeabil
triton
wash
block
pb
contain
bsa
subsequ
cell
incub
rabbit
bacteriophag
bind
specif
phage
coat
protein
phage
dilut
sigma
mous
invitrogen
antibodi
h
room
temperatur
follow
h
incub
secondari
antibodi
dilut
invitrogen
cell
wash
three
time
pb
twice
distil
water
allow
mount
presenc
dapi
sigma
mowiol
mount
medium
prepar
imag
acquir
leica
laser
scan
confoc
microscop
vitro
cell
seed
plate
grown
confluent
cell
incub
target
control
vector
without
h
well
medium
replac
complet
medium
contain
drug
h
plate
place
ice
min
stop
phage
intern
cell
wash
time
pb
cell
surfac
aavp
phage
particl
inactiv
subtilisin
treatment
mgml
min
room
temperatur
subtilisin
inactiv
edta
mm
intern
aavp
particl
obtain
treat
cell
lysi
buffer
deoxychol
acid
mm
ethylen
diamin
tetraacet
acid
mm
tri
ph
h
room
temperatur
number
aavp
particl
count
use
bacteri
infect
count
transduc
unit
tandl
et
al
vivo
experi
carri
adher
uk
coordin
committe
cancer
research
ukcccr
guidelin
welfar
anim
experiment
neoplasia
accord
institut
home
offic
guidelin
mice
anesthet
ga
isofluran
inhal
establish
subcutan
tumor
mice
total
cell
subcutan
implant
immunodefici
nude
mice
tumor
reach
requir
volum
mice
receiv
singl
intraven
dose
tumous
tail
vein
target
control
aavp
bodi
weight
administ
mice
intraperiton
inject
phage
recoveri
experi
xenograft
remov
h
weigh
follow
tumor
grind
incub
tumor
tissu
homogen
host
bacteria
recoveri
integr
infecti
phage
particl
quantifi
tu
normal
tumor
weight
repeat
experi
twice
use
mice
per
group
order
reduc
anim
suffer
appli
reduc
refin
replac
accord
institut
home
offic
guidelin
monitor
luc
transgen
express
whole
live
anim
measur
luc
express
tumor
intraven
administr
carri
luc
report
gene
use
subcutan
tumor
immunodefici
mice
mice
anesthet
administ
mgkg
gold
biotechnolog
subcutan
inject
loos
skin
neck
photon
emiss
imag
time
cours
use
vivo
imag
system
ivi
calip
life
scienc
region
interest
roi
defin
manual
tumor
measur
signal
intens
record
total
photon
count
per
second
per
within
roi
similar
color
scale
bar
appli
repres
imag
statist
analys
perform
use
graphpad
prism
softwar
version
error
bar
repres
standard
error
mean
sem
p
valu
gener
anova
denot
follow
p
p
p
proof
concept
first
want
determin
whether
proteasom
repres
barrier
target
gene
deliveri
thu
transduc
cell
vector
assess
effect
chose
cell
line
initi
experi
cell
extens
use
standard
vitro
model
character
cell
transduct
sinc
express
high
level
integrin
hajit
et
al
hajit
et
al
also
despit
presenc
integrin
subunit
cell
line
mediat
modest
transgen
express
cell
therefor
possibl
vector
abl
access
cell
cytoplasm
efficaci
may
reduc
proteasom
degrad
order
assess
whether
gene
transfer
effici
aavp
reduc
proteasom
activ
efficaci
transduct
evalu
presenc
increas
concentr
cell
incub
control
vector
bear
gfp
luc
report
gene
result
show
effici
strongli
enhanc
overtim
addit
proteasom
inhibitor
instanc
day
maximum
transgen
express
achiev
cell
treatment
result
increas
number
cell
shown
fluoresc
imag
gfp
express
cell
supplementari
figur
data
confirm
quantit
analysi
luc
activ
show
increas
luc
express
cell
cell
supplementari
figur
importantli
luc
activ
detect
cell
receiv
vector
either
alon
combin
supplementari
fig
demonstr
transgen
express
clearli
improv
inhibit
proteasom
next
sought
assess
effect
proteasom
inhibitor
efficaci
gene
deliveri
aavp
vector
cancer
cell
conduct
efficaci
studi
proteasom
inhibit
effici
human
melanoma
cell
known
express
integrin
receptor
ligand
hood
et
al
tandl
et
al
addit
rule
possibl
observ
effect
llnl
tumor
specif
analyz
efficaci
drug
human
rat
glioblastoma
cell
first
set
determin
sensit
cancer
cell
increas
concentr
llnl
thu
cytotox
drug
investig
vitro
cancer
cell
line
tumor
cell
treat
variou
concentr
llnl
rang
compar
cell
cell
line
cell
surviv
presenc
llnl
decreas
concentr
drug
increas
figur
unlik
llnl
cell
viabil
assay
show
toxic
cell
line
cell
rapid
death
cell
alreadi
start
concentr
low
dose
induc
slight
toxic
cell
figur
cytotox
dose
express
valu
correspond
inhibitori
concentr
requir
reduc
cell
surviv
shown
line
graph
approxim
valu
figur
found
cell
death
presenc
induc
cell
cell
cell
death
obtain
respect
figur
llnl
cell
cell
figur
concentr
use
subsequ
experi
assess
effect
gene
deliveri
aavp
vector
rang
caus
littl
toxic
accordingli
select
concentr
cell
cell
contrast
concentr
llnl
test
follow
experi
markedli
higher
reach
cell
initi
analysi
effect
effici
transgen
express
cancer
cell
transduc
tumor
cell
vector
carri
gfp
report
transgen
presenc
absenc
count
monitor
gfp
posit
cell
data
show
gfp
express
gener
stronger
time
cell
receiv
combin
compar
cell
treat
vector
alon
figur
left
panel
instanc
day
transduct
observ
gfp
express
cell
transduc
construct
presenc
compar
cell
transduc
vector
alon
figur
left
panel
also
observ
cell
transduc
gfp
express
presenc
compar
gfp
posit
cell
transduc
vector
alon
respect
figur
left
panel
next
confirm
combin
improv
gene
deliveri
tumor
cell
carri
quantit
analysi
transgen
express
use
vector
express
firefli
luc
report
gene
consist
gfp
report
transgen
express
experi
observ
signific
increas
luc
express
treatment
compar
untreat
transduc
cell
figur
left
panel
instanc
day
transduct
boost
luc
activ
cell
respect
figur
left
panel
confirm
enhanc
cancer
cell
transduct
combin
proteasom
inhibit
uniqu
investig
effect
llnl
addit
proteasom
inhibitor
found
llnl
improv
gene
deliveri
cancer
cell
carri
either
gfp
figur
right
panel
luc
report
gene
figur
right
panel
exampl
day
post
vector
transduct
quantit
analysi
luc
transgen
express
show
addit
llnl
result
fold
fold
fold
increas
luc
activ
cell
respect
figur
right
panel
final
cell
transduc
control
aavp
vector
lack
ligand
also
includ
experi
neg
control
importantli
report
gene
express
detect
cell
receiv
aavp
alon
combin
llnl
figur
b
next
evalu
efficaci
target
gene
deliveri
tumor
system
administr
vector
combin
proteasom
inhibitor
compar
vector
alon
drug
commonli
use
vivo
studi
mice
grime
et
al
use
standard
experiment
setup
vivo
imag
luc
transgen
report
assess
bioluminesc
imag
bli
noninvas
monitor
tempor
dynam
spatial
heterogen
luc
express
live
mice
initi
preclin
model
use
immunodefici
nude
mice
bear
subcutan
tumor
deriv
melanoma
cell
inde
tumor
model
nude
mice
previous
use
assess
efficaci
target
tumor
transduct
vivo
vector
follow
intraven
administr
vector
mice
tandl
et
al
moreov
tumor
cell
induc
moder
grow
tumor
allow
repetit
imag
mice
time
without
reach
larg
size
tumor
avoid
anim
suffer
use
repetit
bli
visual
quantit
luc
express
tumor
time
cours
singl
system
administr
control
vector
alon
combin
consist
previou
report
hajit
et
al
tandl
et
al
luc
express
within
tumor
detect
day
administr
figur
interestingli
enhanc
tumor
express
luc
gene
achiev
day
use
combin
compar
vector
alon
figur
final
bioluminesc
signal
observ
mice
receiv
control
vector
alon
combin
figur
proteasom
mediat
degrad
polyubiquitin
protein
substrat
label
polyubiquitin
chain
zhu
et
al
thu
sought
investig
whether
inhibit
proteasom
lead
increas
polyubiquitin
aavp
phage
coat
protein
perform
experi
cell
line
cell
previous
use
microscop
analysi
intracellular
tandl
et
al
tumor
cell
transduc
either
target
rgdaavp
vector
control
presenc
absenc
subsequ
cell
analyz
aavp
particl
protein
ubiquitin
immunofluoresc
report
neumann
et
al
use
antibodi
ubiquitin
phage
coat
protein
figur
confoc
microscop
analys
show
strong
ubiquitin
aavp
coat
protein
cell
treat
figur
data
prove
accumul
polyubiquitin
aavp
coat
protein
presenc
test
tumor
cell
kill
efficaci
combin
vitro
construct
vector
carri
hsvtk
gene
gene
serv
suicid
gene
combin
gcv
hajit
et
al
trepel
et
al
compar
construct
combin
chose
conduct
experi
human
glioblastoma
model
sinc
tumor
type
highli
aggress
remain
major
challeng
treat
patient
tumor
cell
transduc
target
control
vector
presenc
absenc
hsvtk
suicid
gene
therapi
induc
day
transduct
treatment
gcv
h
h
shown
figur
supplementari
figur
addit
gcv
result
significantli
higher
death
cell
treat
combin
cell
transduc
vector
alon
h
h
treatment
figur
gain
insight
improv
efficaci
gene
deliveri
tumor
cell
kill
follow
proteasom
inhibit
next
investig
effect
persist
phage
particl
tumor
cell
vitro
thu
carri
recoveri
assay
intern
aavphag
particl
presenc
absenc
intracellular
intact
infecti
phage
quantifi
recoveri
cell
lysat
follow
infect
host
bacteria
count
transduc
unit
data
reveal
cell
incub
target
show
signific
phage
intern
figur
confirm
cell
entri
vector
mediat
ligand
sharp
contrast
treatment
cell
transduc
target
result
dramat
increas
fold
recoveri
integr
undamag
intracellular
aavphag
particl
figur
subsequ
sought
investig
whether
inhibit
proteasom
vivo
improv
persist
phage
particl
tumor
system
administr
vector
mice
cohort
mice
bear
subcutan
tumor
receiv
singl
intraven
administr
control
vector
either
alon
combin
intraperiton
administr
h
vector
administr
nude
mice
kill
tumor
collect
rel
tumor
target
quantifi
recoveri
tumor
tissu
homogen
bacteri
infect
count
transduc
unit
importantli
observ
mark
tumor
home
xenograft
combin
figur
specif
found
fold
tumor
enrich
administ
simultan
compar
tumor
home
target
alon
figur
data
establish
proteasom
inhibit
improv
persist
vivo
mice
system
administr
bacteriophag
wide
studi
safe
administ
adult
children
mani
year
fortuna
et
al
recent
even
approv
use
bacteriophag
prepar
food
addit
support
safeti
agent
lang
recent
report
novel
aavp
identifi
promis
vector
target
gene
deliveri
variou
diseas
includ
cancer
howev
due
low
evolut
profil
bacteriophag
bacteria
virus
aavp
vector
confront
sever
barrier
accomplish
effect
gene
deliveri
mammalian
cell
addit
wide
accept
human
cancer
cell
possess
elev
level
proteasom
activ
sensit
proteasom
inhibitor
normal
cell
chen
dou
kisselev
kisselev
goldberg
wu
et
al
take
evid
togeth
hypothes
novel
aavp
vector
may
improv
report
gene
deliveri
thu
increas
cancer
cell
kill
use
conjunct
proteasom
inhibitor
initi
studi
cell
vitro
cellular
model
use
character
transduct
inde
show
modest
gene
express
even
use
high
vector
titer
hajit
et
al
support
notion
aavp
vector
may
subject
high
level
proteasom
degrad
investig
intracellular
barrier
vector
cell
found
cell
transduct
presenc
proteasom
inhibitor
result
strong
increas
gene
transfer
vitro
confirm
block
proteasom
variou
cancer
cell
line
result
increas
report
gfp
luc
transgen
express
data
consist
previou
studi
report
increas
gfp
posit
cell
transduc
cell
lambda
phage
presenc
volci
dewhurst
importantli
bli
luc
experi
show
treatment
mice
boost
target
gene
deliveri
tumor
follow
intraven
administr
report
first
show
efficaci
proteasom
inhibit
drug
target
system
gene
deliveri
tumor
vivo
studi
increas
recoveri
integr
undamag
intracellular
intratumor
aavp
particl
block
proteasom
indic
aavp
phage
particl
fact
suscept
proteasom
degrad
moreov
increas
polyubiquitin
aavp
particl
coat
protein
upon
treatment
confirm
proteasom
degrad
aavp
inde
well
known
proteasom
accomplish
degrad
protein
label
polyubiquitin
chain
glickman
ciechanov
recognit
proteasom
regulatori
complex
polyubiquitin
chain
disassembl
substrat
process
core
proteasom
numer
studi
shown
increas
protein
polyubiquitin
yan
et
al
import
note
mechan
action
also
account
enhanc
effect
cell
transduct
effici
instanc
report
alter
intracellular
traffick
virus
denbi
et
al
yu
lai
howev
report
show
enhanc
nuclear
deliveri
virus
aav
denbi
et
al
studi
report
lysosom
accumul
virus
presenc
yu
lai
present
work
well
studi
souza
et
al
confoc
microscop
imag
intracellular
bacteriophag
show
particl
discret
major
vesicular
local
yet
detect
visibl
alter
vesicular
pattern
particl
follow
treatment
supplementari
figur
recent
found
major
sequest
lysosom
vesicl
upon
entri
cell
minor
cytoplasm
invis
confoc
electron
microscop
imag
unpublish
data
phage
particl
might
also
transient
cytoplasm
passag
enter
cytoplasm
broken
uncoat
shape
also
note
howev
report
inhibit
lysosom
cathepsin
addit
proteasom
tsubuki
et
al
addit
shown
increas
coxsacki
adenoviru
receptor
express
colon
cancer
cell
line
result
enhanc
adenoviru
transfer
target
gene
express
oncolysi
zhang
et
al
date
constantli
observ
associ
improv
aavp
transduct
effici
signific
chang
aavp
distribut
compartment
unnotic
microscop
imag
particular
show
toxic
result
decreas
experiment
effici
caron
et
al
collect
studi
confirm
proteasom
appear
signific
barrier
efficaci
target
gene
deliveri
although
anim
virus
develop
strategi
resist
protect
protein
proteasom
degrad
proteasom
shown
barrier
gene
deliveri
number
eukaryot
virus
lentivir
vector
santoni
de
sio
et
al
virus
viru
also
appear
undergo
ubiquitin
degrad
proteasom
transgen
express
aav
vector
significantli
enhanc
presenc
proteasom
inhibitor
jen
et
al
understand
phage
evolv
infect
bacteria
develop
strategi
overcom
proteasom
barrier
mammalian
cell
render
suscept
proteasom
degrad
vitro
data
effect
efficaci
gene
deliveri
also
confirm
use
llnl
addit
proteasom
inhibitor
howev
find
follow
analysi
effect
llnl
transgen
express
cell
vitro
merit
discuss
although
llnl
stimul
transgen
express
cell
quantit
analysi
luc
express
reveal
signific
differ
cell
transduc
target
alon
cell
receiv
combin
llnl
import
note
llnl
consid
weak
inhibitor
proteasom
compar
exampl
transduct
human
keratinocyt
presenc
llnl
show
signific
differ
transgen
express
et
al
addit
transduct
human
primari
endotheli
cell
much
pronounc
presenc
llnl
denbi
et
al
final
present
studi
effect
llnl
dose
use
improv
efficaci
aavp
dramat
higher
result
show
increas
tumor
cell
kill
interest
addit
show
improv
efficaci
target
tumor
transduct
vivo
intraven
administr
mice
import
intraven
rout
administr
clinic
util
local
metastat
diseas
moreov
proteasom
inhibitor
consid
drug
clinic
trial
treatment
cancer
patient
mujtaba
dou
park
et
al
thu
data
togeth
provid
foundat
use
drug
combin
dual
system
antitumor
therapi
cancer
patient
studi
report
number
novel
find
illustr
proteasom
signific
barrier
target
gene
deliveri
cancer
cell
vitro
well
tumor
vivo
furthermor
confirm
use
combin
proteasom
inhibitor
effici
kill
cancer
cell
either
therapi
alon
drug
consid
futur
clinic
applic
target
system
gene
therapi
aavp
cancer
patient
author
declar
conflict
interest
disclos
